These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20823421)

  • 1. Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen.
    Ferraldeschi R; Howell SJ; Thompson AM; Newman WG
    J Clin Oncol; 2010 Oct; 28(29):e584-5; author reply e586. PubMed ID: 20823421
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
    Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
    J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
    Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
    Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.
    Seruga B; Amir E
    Breast Cancer Res Treat; 2010 Aug; 122(3):609-17. PubMed ID: 20454926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
    Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
    Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inherited gene affects tamoxifen's benefit in some breast cancers.
    Mayo Clin Womens Healthsource; 2006 Jun; 10(6):3. PubMed ID: 16675918
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
    Brauch H; Jordan VC
    Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
    Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
    Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 pharmacogenomics of tamoxifen treatment.
    Technol Eval Cent Assess Program Exec Summ; 2008 May; 23(1):1-4. PubMed ID: 18663817
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.
    Schroth W; Hamann U; Fasching PA; Dauser S; Winter S; Eichelbaum M; Schwab M; Brauch H
    Clin Cancer Res; 2010 Sep; 16(17):4468-77. PubMed ID: 20515869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
    Peppercorn J; A Carey L
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):191-4. PubMed ID: 18279059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do some antidepressants decrease effect of tamoxifen?
    J Support Oncol; 2009; 7(4):147-8. PubMed ID: 19731582
    [No Abstract]   [Full Text] [Related]  

  • 15. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
    Goetz MP; Kamal A; Ames MM
    Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
    Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
    Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?
    Abreu MH; Gomes M; Menezes F; Afonso N; Abreu PH; Medeiros R; Pereira D; Lopes C
    Breast; 2015 Aug; 24(4):481-6. PubMed ID: 25963137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
    Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
    Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 genotype and tamoxifen response.
    Rae JM; Goetz MP; Hayes DF; Ingle JN; Li L; Storniolo AM; Stearns V; Flockhart DA
    Breast Cancer Res; 2005 Jul; 7(5):E6. PubMed ID: 16168100
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy.
    Lash TL; Rosenberg CL
    J Clin Oncol; 2010 Mar; 28(8):1273-5. PubMed ID: 20124162
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.